The GLP-1 class carries the largest safety evidence base any obesity treatment has ever had — well over 142,000 clinical-trial participants across the flagship programs, plus years of post-market surveillance on millions of users. That depth allows something rare: a genuine safety comparison across the class rather than a generic warnings list. Here's what the accumulated data shows.
| Semaglutide | Tirzepatide | Liraglutide | Oral agents (o. sema / orforglipron) | |
|---|---|---|---|---|
| GI side effects (nausea etc.) | Common, dose-dependent, usually transient | Common; comparable family | Common; daily dosing spreads exposure | Common; class-typical |
| Long-horizon outcomes data | Deepest: SELECT (~4 yrs, 17,604 pts) | Growing; large program | Longest market history in class | Newest; accruing |
| Signature cautions | Class warnings* | Class warnings* | Class warnings* | Class warnings*; o. sema absorption rules |
| Discontinuation for side effects | Minority of trial participants | Similar order | Similar order | Similar order |
What the Class Shares
Safety differences within the class are smaller than marketing suggests. Across every agent: gastrointestinal effects dominate (nausea, constipation, diarrhea — typically worst during titration and improving after), and the serious-but-rare tier is a shared list — pancreatitis, gallbladder events, and the boxed thyroid warning derived from rodent findings, which is why personal/family history of medullary thyroid carcinoma or MEN2 contraindicates the whole class. Slowed gastric emptying also matters before anesthesia — surgeons and anesthesiologists now routinely ask.
Where the Profiles Genuinely Differ
- Depth of evidence is semaglutide's safety feature. SELECT's ~four-year, 17,604-patient cardiovascular trial produced not just efficacy but an unusually long, clean safety record — including a mortality benefit. No other agent matches that horizon yet.
- Tirzepatide's higher efficacy, similar tolerability is its quiet safety story: SURMOUNT-era data showed the bigger weight effect without a proportionally worse side-effect burden.
- Liraglutide's differences are practical: daily injections and an older evidence base — its safety record is long, its results modest.
- The new pills are the actuarial youngsters. Nothing alarming has emerged, and orforglipron's Phase 3 program was large — but "approved in 2026" simply means fewer patient-years on the books. Reasonable people weight that.
Reading Safety Like an Adult
Screening Is the Whole Ballgame
Every caution above is exactly why real prescriber screening — history, contraindications, medication review — isn't red tape. Programs with genuine clinical intake are the ones taking the safety data seriously:
Sesame Care
Brand-name route — Rybelsus, oral Wegovy, and injectable brand GLP-1s via low-cost doctor visits.
Flat-rate visits · brand-name FDA-approved medications only
- FDA-approved brand-name medications only
- Fast video visits in most states
- Pairs well with $199 direct-pay channels
RxSpan MD
Physician-led telehealth program with ongoing dose management.
Program pricing shown at checkout
- Physician-led care
- Ongoing dose management
- US pharmacy fulfillment
Compounded medications are not FDA-approved. They are prepared by licensed pharmacies but have not been evaluated by the FDA for safety, effectiveness, or quality.
Visit RxSpan MD Paid linkCare Bare Rx
Telehealth GLP-1 program with both injectable and oral options in intake.
Pricing shown after provider intake
- Injectable and oral options
- Licensed US providers
- Quick eligibility check
Compounded medications are not FDA-approved. They are prepared by licensed pharmacies but have not been evaluated by the FDA for safety, effectiveness, or quality.
Try Gala GLP-1 instead Paid linkBottom Line
No medication class this new has ever been this thoroughly watched. The data says the honest sentence plainly: well-screened patients face mostly transient GI effects, rare serious risks their provider screens for, and — per the largest trial — better survival odds treated than not.
Last updated August 2026. This is general information, not a substitute for prescriber screening of your individual risk factors.
See the Full Comparison Grid
Every provider and channel we track — price, format, and what's included — side by side.
Compare All ProvidersMore Comparisons
The Compounded Market in 2026: State of Play
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. All prescription medications discussed require evaluation by a licensed healthcare provider. Always consult your doctor before starting, stopping, or changing any medication. Individual results vary.
Affiliate Disclosure: CompareGLP-1 may earn a commission when you use links on this page, at no additional cost to you. Links marked "Paid link" are sponsored. Our comparisons are editorially independent — rankings and verdicts are never sold, and we never fabricate statistics, testimonials, or reviews.